R&D areas-We think a true scientist is a person who walk towards truth with a sense of awe and respect without distorting the truth.We are walking this way today in an undemonstrative fashion to become scientists who embody this tenet.

Immunotherapeutic cells and antibodies

H > Projects > Cancer

Immune modulation & anti-tumor effects

What is immunotherapy?

We stay healthy because our immune system constantly monitors and eliminates invading bacteria, viruses, and abnormal cells. The immune system is designed to distinguish between our own and foreign cells, and between normal and diseased cells.

Immunotherapy is a therapeutic approach designed to treat diseases, such as infection and cancer, by harnessing the power of the immune system. Antibody-based therapies are currently the most common form of immunotherapy. Other immunotherapies include immunomodulatory cytokines, prophylactic or therapeutic vaccines, and immune cell therapies. The goal of these medicines is to augment the body's own immune system to combat disease. Today, immunotherapies are being used successfully to treat a variety of diseases, including cancer, infections, and autoimmune diseases.

R&D trends

Immunotherapy initially comprised the therapeutic application of cytokines, such as interleukins and interferons, which improve the overall function of the immune system. This was followed by the development of T cell therapies that elicit immune reactions against specific antigens, antigen-derived peptide drugs that boost immune reactions against target antigens, monoclonal antibodies that target specific tumor antigens, and most recently, immunoregulatory antibodies that block immunosuppressive molecules. These immunoregulatory antibodies have the potential to prevent immunosuppression in certain groups of patients. We know that conventional cytotoxic chemotherapy, which inhibits tumor cells largely by inhibiting proliferation and inducing apoptosis, is not an effective way of controlling the tumor microenvironment. Therefore, finding effective immunotherapies to treat cancer is a promising strategy. Two examples of such therapies are Ipilimumab, an immunomodulatory monoclonal antibody against CTLA-4 that is used to treat melanoma, and Provenge, an autologous dendritic cell therapy for the treatment of prostate cancer. At MI, we are currently investigating a variety of such cell-based and antibody immunotherapies.

MOGAM conducts...

Research on targeted therapies and is committed to using translational research to develop personalized therapies that take into account the characteristics of each individual patient.